Fujifilm, Regeneron in 10-Year, $3-Bn US Mfg Pact
Fujifilm Diosynth Biotechnologies, a CDMO of biologics and advanced therapies, has entered a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, to provide US-based production of its biologic medicines.
Under the agreement, Fujifilm will provide US-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new large-scale biomanufacturing facility in Holly Springs, North Carolina, when the site begins operations later this year (2025).
Fujifilm Diosynth Biotechnologies will be bringing additional capacity on line in 2025, 2026 and beyond as it completes a current $7-billion of expansion plan underway in both Europe and the US.
